OBJECTIVE: To review the efficacy of Tianshu capsule in the treatment of migraine. METHODS: Retrieving papers from Pubmed, cochrane central register of controlled trials (CENTRAL), Weipu database (VIP), China biology medicine (CBM), China national knowledge infrastructure (CNKI), and Wanfang Data. Two reviewers retrieved and extracted the information independently. Retrieval time scale is up to August 2012. Software Review Manager 5.1 was used for analysis. RESULTS: A total of 10 studies including 937 migraine patients. The merged data shows Tianshu capsule had a higher effective rate in treating migraine, and there is no significant heterogeneity between Tianshu capsule group and control group (Chi2 = 6.33, df = 9, P = 0.71, I2 = 0%), OR = 4.18 [95% CI (2.93,5.95)]. Tianshu capsule alone compared to conventional therapy also showed advantages, and there was low heterogeneity (chi2 = 4.53, df = 3, P = 0.21, I2 = 34%), OR = 3.95 [95% CI (2.32, 6.72)]. Meta-analysis results show that clinical efficacy of Tianshu capsule was better than that of the control group in the treatment of migraine and there was a significant difference (P < 0.000 01). CONCLUSION: Tianshu capsule had better efficacy in the treatment of migraine with fewer adverse effects.
OBJECTIVE: To review the efficacy of Tianshu capsule in the treatment of migraine. METHODS: Retrieving papers from Pubmed, cochrane central register of controlled trials (CENTRAL), Weipu database (VIP), China biology medicine (CBM), China national knowledge infrastructure (CNKI), and Wanfang Data. Two reviewers retrieved and extracted the information independently. Retrieval time scale is up to August 2012. Software Review Manager 5.1 was used for analysis. RESULTS: A total of 10 studies including 937 migrainepatients. The merged data shows Tianshu capsule had a higher effective rate in treating migraine, and there is no significant heterogeneity between Tianshu capsule group and control group (Chi2 = 6.33, df = 9, P = 0.71, I2 = 0%), OR = 4.18 [95% CI (2.93,5.95)]. Tianshu capsule alone compared to conventional therapy also showed advantages, and there was low heterogeneity (chi2 = 4.53, df = 3, P = 0.21, I2 = 34%), OR = 3.95 [95% CI (2.32, 6.72)]. Meta-analysis results show that clinical efficacy of Tianshu capsule was better than that of the control group in the treatment of migraine and there was a significant difference (P < 0.000 01). CONCLUSION: Tianshu capsule had better efficacy in the treatment of migraine with fewer adverse effects.